Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
America’s drug price hike conundrum in backdrop of 2019 Medicare Part D data
Nearly every
year, drugmakers ring in the new year with drug price increases in the US. This
year
Analyzing over US$ 90 billion of Medicare Prescription Drug (Part D) Spending in 2016
This week, PharmaCompass
reviews the recently released data on prescription drugs paid for under th
Divi’s Labs on FDA’s Import Alert List; but did it refuse an inspection?
Divi's Laboratories — an Indian active pharmaceutical ingredient (API) manufacturer and until
Teva CEO steps down; FDA Warning Letters to firms in Japan, India & China
This week, Phispers highlights more bad news for Israeli drugmaker Teva, along with news on the &lsq
Drug costs and prescription trends in the United States: Analyzing Medicare’s $121 billion spend
In less than three weeks, Donald Trump will assume office as the
President of the United States. He
China shuts plants of major antibiotic producers to fight pollution; more troubles for Teva
This week, Phispers has lots on generics. While the global leader Teva has more troubles at hand, ge
